We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Global X China Biotech Innovations ETF | NASDAQ:CHB | NASDAQ | Exchange Traded Fund |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.64 | 2.67 | 10.66 | 0 | 01:00:00 |
RNS Number:8085N UBS AG (EMM) 22 July 2003 FORM 38.5 (SUMMARY) Lodge with Company Announcements Office and the Panel. Use a separate form for each class of securities in which dealings have been made. CONNECTED EXEMPT MARKET-MAKERS: DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS Name of EMM UBS AG .................................................................................... Date of disclosure 22 July 2003 .................................................................................... Contact Name Brenton Amedee .................................................................................... Telephone number 020-7568 4981 .................................................................................... Please see attached disclosure of dealings under Rule 38.5 in the securities of the following companies: British Biotech -Contract For Difference Chubb Plc - Contract For Difference Debenhams Plc - Contract For Difference _______________________________________ AMENDMENT If the attached Rule 38.5 disclosure is to amend a previous disclosure, please state which element(s) of previous disclosure was incorrect: In the case of option business or dealings in derivatives full details should be given on a separate sheet so that the nature of the dealings can be fully understood. For options this should include the number of securities under option, the exercise period (or in the case of exercise, the exercise date), the exercise price and any option money paid or received. For derivatives this should include, at least, the number of reference securities to which they relate (when relevant), the maturity date (or if applicable the closing out date) and the reference price. For full details of disclosure requirements see Rules 8 and 38 of the Code. If in doubt contact the Monitoring Section of the Panel, Tel No: 020-7638 0129. CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS: DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS Dealing in Contract for Differences ("CFD") referenced to...British Biotech Plc, Ord 0.10 Date of Disclosure: 22 July 2003 Date of Dealing 21 Jul 2003 Name of EMM/EPT... UBS AG Name of offeree / offeror with whom connected Vernalis Group Plc Product Type.........(long/short) CFD Long Maturity Date 21 Apr 2004 Writing of CFD Number of securities to which the CFD is referenced 50,000 CFD reference price: (High) 0.68 GBP............................(Low) 0.68 GBP ........................... Closing out of CFD Number of securities to which the CFD is referenced 0 CFD reference price: (High) 0 GBP (Low) 0 GBP Further disclosure should be made where necessary so that the nature of the dealings can be fully understood. CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS: DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS Dealing in Contract for Differences ("CFD") referenced to...British Biotech Plc, Ord 0.10 Date of Disclosure: 22 July 2003 Date of Dealing 21 Jul 2003 Name of EMM/EPT... UBS AG Name of offeree / offeror with whom connected Vernalis Group Plc Product Type.........(long/short) CFD Short Maturity Date 16 Apr 2004 Writing of CFD Number of securities to which the CFD is referenced 0 CFD reference price: (High) 0 GBP............................(Low) 0 GBP...... ..................... Closing out of CFD Number of securities to which the CFD is referenced 13,380 CFD reference price: (High) 0.68 GBP (Low) 0.68 GBP Further disclosure should be made where necessary so that the nature of the dealings can be fully understood. CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS: DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS Dealing in Contract for Differences ("CFD") referenced to Chubb Plc, Ord 0.36 Date of Disclosure: 22 July 2003 Date of Dealing 21 Jul 2003 Name of EMM/EPT... UBS AG Name of offeree / offeror with whom connected United Technologies Corporation Product Type.........(long/short) CFD Short Maturity Date 09 Apr 2004 Writing of CFD Number of securities to which the CFD is referenced 0 CFD reference price: (High) 0 GBP............................(Low) 0 GBP...... ..................... Closing out of CFD Number of securities to which the CFD is referenced 1,509,100 CFD reference price: (High) 0.76 GBP (Low) 0.76 GBP Further disclosure should be made where necessary so that the nature of the dealings can be fully understood. CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS: DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS Dealing in Contract for Differences ("CFD") referenced to...Debenhams Plc, Ord 0.10 Date of Disclosure: 22 July 2003 Date of Dealing 21 July 2003 Name of EMM/EPT... UBS AG Name of offeree / offeror with whom connected Permira Product Type.........(long/short) CFD Long Maturity Date 21 Apr 2004 Writing of CFD Number of securities to which the CFD is referenced 34,806 CFD reference price: (High) 4.17 GBP............................(Low) 4.17 GBP ........................... Closing out of CFD Number of securities to which the CFD is referenced 0 CFD reference price: (High) 0 GBP (Low) 0 GBP Further disclosure should be made where necessary so that the nature of the dealings can be fully understood. This information is provided by RNS The company news service from the London Stock Exchange END EMMNKBKNKBKDAOB
1 Year Global X China Biotech I... Chart |
1 Month Global X China Biotech I... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions